Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Inclusion Criteria: * Preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age * Bilateral type 1 ROP with one of the following retinal findings in each eye * Zone I, stage 1+, 2+, 3+/- disease, or * Zone II, stage 2+, 3+, disease, or * A-ROP Exclusion Criteria: * Preterm infants with stage 4 or 5 ROP in one or both eyes * Have received any previous surgical or nonsurgical treatment for ROP, including laser photocoagulation, anti-VEGF therapy, vitrectomy * Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy) * Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer * Have active ocular infection within 5 days before or on the day of first investigational treatment * Have a history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes * Have any contraindication for intravitreal injection clearly stated in the instructions * Have any ocular structural abnormality that may affect efficacy assessments * Have a history of any other congenital or systemic conditions that are assessed by the investigator to have a significant risk of severe impact on visual function * Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments